203 related articles for article (PubMed ID: 22424737)
1. V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.
Berro R; Klasse PJ; Jakobsen MR; Gorry PR; Moore JP; Sanders RW
Virology; 2012 Jun; 427(2):158-65. PubMed ID: 22424737
[TBL] [Abstract][Full Text] [Related]
2. A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.
Tilton JC; Wilen CB; Didigu CA; Sinha R; Harrison JE; Agrawal-Gamse C; Henning EA; Bushman FD; Martin JN; Deeks SG; Doms RW
J Virol; 2010 Oct; 84(20):10863-76. PubMed ID: 20702642
[TBL] [Abstract][Full Text] [Related]
3. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Henrich TJ; Tsibris AM; Lewine NR; Konstantinidis I; Leopold KE; Sagar M; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):420-7. PubMed ID: 20856130
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.
Roche M; Jakobsen MR; Sterjovski J; Ellett A; Posta F; Lee B; Jubb B; Westby M; Lewin SR; Ramsland PA; Churchill MJ; Gorry PR
J Virol; 2011 May; 85(9):4330-42. PubMed ID: 21345957
[TBL] [Abstract][Full Text] [Related]
6. A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
Moore JP; Kuritzkes DR
Curr Opin HIV AIDS; 2009 Mar; 4(2):118-24. PubMed ID: 19339950
[TBL] [Abstract][Full Text] [Related]
7. Use of G-protein-coupled and -uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.
Berro R; Yasmeen A; Abrol R; Trzaskowski B; Abi-Habib S; Grunbeck A; Lascano D; Goddard WA; Klasse PJ; Sakmar TP; Moore JP
J Virol; 2013 Jun; 87(12):6569-81. PubMed ID: 23468486
[TBL] [Abstract][Full Text] [Related]
8. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
[TBL] [Abstract][Full Text] [Related]
9. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.
Westby M; Smith-Burchnell C; Mori J; Lewis M; Mosley M; Stockdale M; Dorr P; Ciaramella G; Perros M
J Virol; 2007 Mar; 81(5):2359-71. PubMed ID: 17182681
[TBL] [Abstract][Full Text] [Related]
10. A single-residue change in the HIV-1 V3 loop associated with maraviroc resistance impairs CCR5 binding affinity while increasing replicative capacity.
Garcia-Perez J; Staropoli I; Azoulay S; Heinrich JT; Cascajero A; Colin P; Lortat-Jacob H; Arenzana-Seisdedos F; Alcami J; Kellenberger E; Lagane B
Retrovirology; 2015 Jun; 12():50. PubMed ID: 26081316
[TBL] [Abstract][Full Text] [Related]
11. Structure and dynamics of the gp120 V3 loop that confers noncompetitive resistance in R5 HIV-1(JR-FL) to maraviroc.
Yuan Y; Yokoyama M; Maeda Y; Terasawa H; Harada S; Sato H; Yusa K
PLoS One; 2013; 8(6):e65115. PubMed ID: 23840315
[TBL] [Abstract][Full Text] [Related]
12. [Mechanisms of resistance and failure of treatment with maraviroc].
Delgado R
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():28-33. PubMed ID: 19133219
[TBL] [Abstract][Full Text] [Related]
13. A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations.
Roche M; Salimi H; Duncan R; Wilkinson BL; Chikere K; Moore MS; Webb NE; Zappi H; Sterjovski J; Flynn JK; Ellett A; Gray LR; Lee B; Jubb B; Westby M; Ramsland PA; Lewin SR; Payne RJ; Churchill MJ; Gorry PR
Retrovirology; 2013 Apr; 10():43. PubMed ID: 23602046
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
[TBL] [Abstract][Full Text] [Related]
15. Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.
Soulié C; Malet I; Lambert-Niclot S; Tubiana R; Thévenin M; Simon A; Murphy R; Katlama C; Calvez V; Marcelin AG
AIDS; 2008 Oct; 22(16):2212-4. PubMed ID: 18832886
[TBL] [Abstract][Full Text] [Related]
16. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.
Berro R; Klasse PJ; Lascano D; Flegler A; Nagashima KA; Sanders RW; Sakmar TP; Hope TJ; Moore JP
J Virol; 2011 Aug; 85(16):8227-40. PubMed ID: 21680525
[TBL] [Abstract][Full Text] [Related]
17. Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence.
Delobel P; Cazabat M; Saliou A; Loiseau C; Coassin L; Raymond S; Requena M; Marchou B; Massip P; Izopet J
J Antimicrob Chemother; 2013 Nov; 68(11):2506-14. PubMed ID: 23794603
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120.
Ratcliff AN; Shi W; Arts EJ
J Virol; 2013 Jan; 87(2):923-34. PubMed ID: 23135713
[TBL] [Abstract][Full Text] [Related]
19. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.
Ogert RA; Hou Y; Ba L; Wojcik L; Qiu P; Murgolo N; Duca J; Dunkle LM; Ralston R; Howe JA
Virology; 2010 Apr; 400(1):145-55. PubMed ID: 20172579
[TBL] [Abstract][Full Text] [Related]
20. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.
Murga JD; Franti M; Pevear DC; Maddon PJ; Olson WC
Antimicrob Agents Chemother; 2006 Oct; 50(10):3289-96. PubMed ID: 17005807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
